Engages in biopharmaceutical research and development

EpiPharm AG is a clinical-stage biopharmaceutical company focused on development to market of innovative, non-invasive, take home topical products for the treatment of benign skin tumours and hyperpigmentation disorders.

Elsohly Laboratories, Inc. provides drug testing laboratories and services. Its laboratory performs testing for drugs of abuse, reference analyses for commercial and governmental clients, preparing and shipping blind quality control specimens, laboratory controls, standards and internal standards, and performing research and development activities?. The company was founded in 1985 and is headquartered in Oxford, MS.

Sichuan Kelun Pharmaceutical Co., Ltd. engages in research, development, manufacture, and sale of pharmaceutical products. Its products include large volume injection (infusion), small capacity injection (water injection), sterile powder injection, tablets, capsules, granules, oral solution, and peritoneum. It also provides dialysate and antibiotic intermediates, raw materials, pharmaceutical packaging materials, medical equipment, and other medical products. The company was founded by Ge Xin Liu in 1996 and is headquartered in Chengdu, China.

LANXESS is a biotechnology firm that distributes chemical products to its clients. The company’s product portfolio consists of REACH, advanced intermediaries, performance chemicals, performance materials, and ARLANXEO. REACH provides chemical substance handling solutions by offering registration, evaluation, authorization, and restriction of chemicals. LANXESS was founded in 2004 and is based in Cologne.

Hubei Wudang Animal Pharmaceutical Co., Ltd., established on 2003-05-29, Business scope includes licensed projects:Veterinary drug production;Veterinary drug business;Feed additive production;road freight transport(Web Freight);Disinfectant production(Free of Hazardous Chemicals);Cosmetic production;Basic Telecom Services;The first type of value-added telecommunications services;The second type of value-added telecommunications services(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Feed Additive Sales;production of agricultural products,Sales,processing,transportation,Storage and other related services;Disinfectant sales(Free of Hazardous Chemicals);Daily necessities sales;daily mask(non-medical)Sales;Cosmetics Retail;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Medical Mask Retail;real estate herbal medicine(Does not contain Chinese herbal medicine)buy and sell;Non-residential real estate leases;housing lease(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Chongqing Jianqiao Pharmaceutical Development Co., Ltd., established on 1999-02-08, The scope of business includes research on Chinese and Western medicines and bioengineering products,Medical Technology Services(Except for the special provisions of the state in the scope of business)."The above scope of law,Do not operate if prohibited by laws and regulations;law,Regulations stipulate that approval should be obtained and no operation shall be conducted without approval].★★

Saltigo GmbH engages in the custom synthesis of chemical active ingredients and intermediates. It manufactures intermediates and active ingredients for the crop protection market; pharmaceutical intermediates and active pharmaceutical ingredients for pharmaceutical companies; and fine chemicals for non-life-science applications that include oils and waxes for industrial and cosmetic purposes, scents and aromas for cosmetics and foods, plastic additives for PVC and synthetic rubbers, special adhesives for the footwear industry, and chemicals for manufacturing OLEDs and similar compounds found in flat screens and solar modules. The company was founded in April 2006 and is headquartered in Leverkusen, Germany.

Boehringer Ingelheim KG, part of C.H. Boehringer Sohn AG & Co. KG, is a company headquartered in Biberach, Germany. The firm wholesales pharmaceutical products. It was founded in 1981.

Da Zen Theranostics develop a product that can target cancer cells, function as a contrast agent to improve the visibility of cancer cells. It functions as a contrast agent to improve the visibility of cancer cells during diagnostic imaging and deliver a therapeutic drug to destroy cancerous cells. The product will be based on a chemical compound that was created by Dr. Maged Henary, associate professor of chemistry at Georgia State. Henary’s chemical compound, a heptamethine cyanine also known to the scientific community as MHI-148, is already being used internationally in cancer imaging research. The company was founded in 2017 and is based in San Jose, California.

Calyx Chemicals & Pharmaceuticals Ltd. engages in the manufacture of active pharmaceutical ingredients and intermediates. It also provides antibiotics and antidiabetics as well as custom syntheses services. The company was founded by Smitesh Chandravadan Shah in 1979 and is headquartered in Mumbai, India.

StylaCats Ltd. operates as a contract research organization that develops catalysts and reagents for the chemical and life science industries.

Zhengzhou Renhong Pharmaceutical Technology Co., Ltd., established on 2015-11-20, The scope of business includes the development of medical technology,technology transfer;Sales of medical equipment,technical consulting,Technical Services;Technology development of computer hardware and software,technology transfer,technical consulting,Technical Services;Computer Data Processing Services;Computer System Integration Services.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Manufactures and markets personal care products

Shenyang Pharmaceutical University (Benxi) Pharmaceutical Technology Co., Ltd., established on 2011-10-31, Business scope includes pharmaceuticals,food,Nutrients,Health Supplies,Diagnostic reagents,R&D of healthcare medical devices,technology transfer,Technical Advisory Services,Technology Park Management Services,Technology business incubation service,Biomedical Testing Services,Property Management Services,Technology training service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Zhongke Blue Ocean Testing (Tianjin) Technology Co., Ltd., established on 2019-11-27, Business scope includes biomedicine,Biological product,Healthy food,cosmetic,Class Ι and Class Ⅱ medical devices,Agriculture and animal husbandry technology development,technical consulting,Technology Promotion,Technical Services,technology transfer;Conference Services;Labor protection supplies,Office Supplies,stationery,electronic product,Computer hardware and software,Instrumentation,plastic products,Experimental analysis instrument,Chemical Reagents and Auxiliaries(Hazardous chemicals and flammable and explosive precursors are excluded),Biological product,cosmetic,Sales of class Ι and class Ⅱ medical devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Zhejiang Laiyi Biotechnology Co., Ltd., established on 2003-07-21, Business scope includes licensed projects:Pesticide production;Pesticide Wholesale;pharmaceutical production;food production;Import and export;Feed additive production;Hazardous Chemical Production;Disinfectant production(Free of Hazardous Chemicals)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Research and development of bio-based material polymerization technology;Manufacturing of bio-based materials;Research and development of biopesticide technology;Chemical product production(No licensed chemical products);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Disinfectant sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).